BCUS - ETF AI Analysis

Top Page

Bancreek U.S. Large Cap ETF (BCUS)

Rating:74Outperform

Price Target:―

BCUS, the Bancreek U.S. Large Cap ETF, earns a solid overall rating thanks to several high-quality holdings like Parker Hannifin and Boston Scientific, which show strong financial performance, positive earnings calls, and healthy growth prospects. Other key positions such as Amphenol, InterDigital, and CRH also support the fund’s quality, though concerns about high valuations, leverage, and some bearish or mixed technical signals in names like Cardinal Health, Transdigm Group, and Casey’s General Stores slightly weigh on the rating. The main risk factor is that many top holdings face valuation and leverage concerns at the same time, which could increase the fund’s sensitivity to market pullbacks.

Positive Factors

Strong Leading Holdings

Several of the largest positions, such as Curtiss-Wright, Amphenol, and WW Grainger, have shown strong gains, helping support the ETF’s overall performance.

Broad Sector Mix

The fund spreads its investments across multiple sectors, including industrials, technology, financials, health care, and consumer stocks, which helps reduce reliance on any single industry.

Positive Recent Performance

The ETF has delivered steady gains over the past month, three months, and year-to-date, indicating generally favorable recent results for investors.

Negative Factors

High Industrial Sector Concentration

Nearly one-third of the portfolio is in industrial companies, so a downturn in this sector could have an outsized impact on the fund.

Mixed Results Among Top Holdings

Some major positions like Trane Technologies, CRH, AbbVie, and JPMorgan have shown weak or negative performance, which can drag on the ETF’s returns.

Relatively High Expense Ratio

The fund’s expense ratio is on the higher side for a large-cap U.S. ETF, meaning more of the investment return is used to cover fees.

BCUS vs. SPDR S&P 500 ETF (SPY)

AUM109.03M

RegionNorth America

Expense Ratio0.70%

Beta0.89

IssuerBancreek

Inception DateDec 21, 2023

Dividend Yield0.47%

Asset ClassEquity

Index TrackedNo Underlying Index

Share Statistics

EPS (TTM)N/A

Shares OutstandingN/A

10 Day Avg. Volume9,349

30 Day Avg. Volume7,110

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

38.94

Price Target Upside― Downside

Rating ConsensusStrong Buy

Number of Analyst Covering30

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

BCUS Summary

The Bancreek U.S. Large Cap ETF (BCUS) is an exchange-traded fund that invests mainly in large, well-established U.S. companies, without tracking a specific index. It focuses on big businesses across many sectors, including industrials, technology, finance, and health care. Well-known holdings include JPMorgan Chase and AbbVie. Someone might invest in BCUS to get broad diversification in leading U.S. companies and seek long-term growth with the relative stability that large firms can offer. However, the fund can still go up and down with the overall stock market, so your investment value may fluctuate.

How much will it cost me?The Bancreek U.S. Large Cap ETF (BCUS) has an expense ratio of 0.7%, which means you’ll pay $7 per year for every $1,000 invested. This is higher than average because the fund is actively managed, requiring more resources to select and monitor investments compared to passively managed ETFs that track an index.

What would affect this ETF?The Bancreek U.S. Large Cap ETF (BCUS) could benefit from positive trends in the U.S. economy, such as technological innovation and industrial growth, which align with its significant exposure to the Technology and Industrials sectors. However, rising interest rates or economic slowdowns could negatively impact consumer spending and financial sector performance, which are also key components of the fund. Regulatory changes or geopolitical tensions affecting large-cap companies may further influence the ETF's future performance.

BCUS Top 10 Holdings

BCUS is leaning heavily into U.S. industrial powerhouses, with names like Trane Technologies and Parker Hannifin doing much of the heavy lifting as their shares keep climbing on solid earnings and growth stories. InterDigital and Cardinal Health add a tech-and-healthcare twist, both rising steadily and helping smooth out bumps. On the flip side, Boston Scientific has been losing steam lately, acting as a drag, while TransDigm feels more like it’s idling than accelerating. Overall, this is a U.S.-centric, large-cap fund with an industrial tilt and selective exposure to tech and health care.

Name	Company Name	Weight %	Market Value	Market Cap	Yearly Gain	Overall Rating
IDCC	InterDigital	4.61%	$5.02M	$9.73B	84.72%	76 Outperform
CAH	Cardinal Health	4.24%	$4.62M	$54.09B	77.95%	66 Neutral
CASY	Casey's General	4.05%	$4.41M	$25.47B	68.38%	68 Neutral
TT	Trane Technologies	4.03%	$4.39M	$103.18B	35.83%	70 Outperform
PH	Parker Hannifin	3.98%	$4.34M	$127.66B	61.85%	79 Outperform
APH	Amphenol	3.97%	$4.32M	$166.14B	113.02%	78 Outperform
TDG	Transdigm Group	3.97%	$4.32M	$74.33B	-3.98%	69 Neutral
BSX	Boston Scientific	3.85%	$4.20M	$113.10B	-26.44%	79 Outperform
CRH	CRH plc	3.66%	$3.98M	£58.68B	20.34%	76 Outperform
JPM	JPMorgan Chase	3.58%	$3.90M	$802.53B	18.90%	72 Outperform

BCUS Technical Analysis

Technical Analysis Sentiment

Positive

Last Price―

Price Trends

50DMA

33.02

Positive

100DMA

32.60

Positive

200DMA

32.16

Positive

Market Momentum

MACD

0.25

Negative

RSI

55.95

Neutral

STOCH

73.08

Neutral

Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For BCUS, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 33.44, equal to the 50-day MA of 33.02, and equal to the 200-day MA of 32.16, indicating a bullish trend. The MACD of 0.25 indicates Negative momentum. The RSI at 55.95 is Neutral, neither overbought nor oversold. The STOCH value of 73.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BCUS.

BCUS Peer Comparison

Comparison Results

Name	Price	Price Target	AUM	Expense Ratio	Overall Rating
BCUS	―	―	$109.03M	0.70%	74 Outperform
NBCR	―	―	$880.47M	0.29%	73 Outperform
MODL	―	―	$862.75M	0.46%	74 Outperform
BALI	―	―	$845.44M	0.35%	72 Outperform
DSPY	―	―	$806.44M	0.18%	73 Outperform
LRGC	―	―	$789.74M	0.39%	74 Outperform

Performance Comparison

BCUS

Bancreek U.S. Large Cap ETF

33.45

4.10

13.97%

NBCR

Neuberger Berman Core Equity ETF

―

MODL

VictoryShares WestEnd U.S. Sector ETF

―

BALI

BlackRock Advantage Large Cap Income ETF

―

DSPY

Tema S&P 500 Historical Weight ETF Strategy

―

LRGC

AB US Large Cap Strategic Equities ETF

―

Glossary

BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―

Table of Contents